News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
US spot Bitcoin ETFs continue net inflow streak, reaching $365 million on sixth day
U.S. spot bitcoin ETFs saw net inflows worth $365.5 million on Thursday.The inflows were led by Ark Invest and 21Shares’ $113.8 million.
The Block·2024/09/27 06:03
Robinhood and Revolut consider entering stablecoin market
Grafa·2024/09/27 04:20
Ethereum Price Eyes Bitcoin’s Lead: Can It Climb to a New Weekly High?
Newsbtc·2024/09/27 04:12
Curve Finance considers Excluding TUSD as Collateral After SEC Charges
Cryptonewsland·2024/09/26 23:33
Invest Smart: Leading Cryptos with Rapid Profit Potential
Cryptonewsland·2024/09/26 23:33
Stacks (STX) makes 30% gain as mainnet upgrade and stablecoin launch approach
Cointelegraph·2024/09/26 22:42
XRP Whales Trigger Worry With $23.4M Token Shift – Is a Sell-off Coming?
Binance's reserve of XRP tokens has increased substantially in the past fortnight, but this doesn't necessarily indicate an imminent dump.
CryptoNews·2024/09/26 22:36
Analytics Firm Reveals Critical Level Bitcoin Needs to Hold For Bullish Sentiment to Continue
Bitcoinsistemi·2024/09/26 21:39
Boost Your Budget with ADA, XRP, WIF, MTAUR: Top Growth Coins
Cryptotimes·2024/09/26 20:57
Flash
20:09
Five Below shares dropped 8% in after-hours US tradingThe company's net sales in the first quarter were $1.29 billion.
20:06
U.S. stocks close lower: the three major indexes ended in the red, NVIDIA fell more than 3%According to Golden Ten Data on June 4, U.S. stocks closed lower on Wednesday, with the Dow Jones initially down 1.2%, the S&P 500 down 0.7%, and the Nasdaq down 0.89%. Microsoft (MSFT.O) and NVIDIA (NVDA.O) both fell more than 3%, Oracle (ORCL.N) dropped over 5%, while Intel (INTC.O) rose 4%. The Nasdaq Golden Dragon China Index closed down 2.46%, with Alibaba (BABA.N) slipping more than 2%.
20:06
Verastem Oncology announced that its oral, potential best-in-class investigational KRAS G12D (on/off) inhibitor VS-7375 has received Fast Track designation from the U.S. Food and Drug Administration (FDA).This medication is intended for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying the KRAS G12D mutation. Fast Track designation is designed to accelerate the development and review process for drugs aimed at serious conditions that address unmet medical needs. This designation means that VS-7375 has the potential to address the critical clinical need in KRAS G12D-mutant NSCLC. For Verastem, this represents an important regulatory milestone in advancing its product pipeline.
News